Research note
What is BPC-157 peptide? Structure, mechanisms and research applications
BPC-157 research peptides explained: what is BPC-157 peptide used for, how it acts on blood vessels and repair cells, what animal and human studies report, and is it safe? A clear, source-based overview for laboratory work. Research use only.
BPC-157 is a synthetic peptide made of 15 amino acids (GEPPPGKPADDAGLV). Its sequence reproduces a fragment of a protective protein isolated from human gastric juice, and research on it centres on a possible role in tissue repair. Since the early 1990s, labs have tested it on cultured cells and in animals with injured tendons, ligaments, muscles, gut lining and blood vessels. For now its place is the laboratory bench: the peptide has no approved medical use and is handled as a research material.
What is BPC-157 peptide?
Body Protection Compound 157 – that is what the abbreviation stands for. Predrag Sikirić’s team at the University of Zagreb described a protective protein from gastric juice and called it BPC. They then turned their attention to one 15-residue sequence associated with it and reported that this fragment showed activity in their experimental models. That sequence is what researchers today know as BPC-157. Anyone digging through the older literature will also meet it under its development codes, PL 14736, PL-10 and PLD-116. The earliest papers counted in a 2025 systematic review appeared in 1993.The material used in laboratories today is made by solid-phase peptide synthesis rather than extracted from gastric juice.A chain of 15 residues is short, and short peptides rarely last long in the gut: digestive enzymes take most of them apart quickly. That is what makes BPC-157 worth a second look. The authors of the earliest papers reported that it remained relatively stable under the conditions they examined. Why it holds up has still not been established. A 2025 review of the literature and patents proposes one candidate: the glycine at the N-terminus, which may contribute to resistance against protease degradation. For a laboratory that is a reason to ask how the sequence behaves in other experimental environments, not a basis for assuming it survives every storage condition or formulation.
What is BPC-157 peptide used for in research?
Tissue repair is never one process, which is precisely what makes it hard to study. A torn tendon sets several jobs running at once. The body has to restore blood supply, move repair cells into the gap, build fresh collagen and keep the inflammation that followed the injury under control. None of these runs in isolation, and a change in one shows up in the others. BPC-157 research peptides are used to probe those interactions in laboratory settings, not as an established treatment for any single injury.What drew attention in the first place was the range of tissues involved. Reports of a single 15-amino-acid sequence influencing repair in tendon, ligament, skeletal muscle, bone, gastric mucosa, skin and blood vessels raise an obvious question: what does it do across such different tissues? Is the peptide acting on something they all share? That question still shapes the laboratory work, and most BPC-157 research studies now sit in five broad areas:musculoskeletal soft-tissue repair, covering tendon, ligament, muscle and the junctions between them and bone;protection of the gastrointestinal mucosa, the original context in which the peptide was developed;skin wound healing and angiogenesis;vascular tone and the nitric oxide system;neural models, including central nervous system disorders.A 2025 systematic review gives some sense of the scale. Working within orthopaedic sports medicine alone, the authors went through 544 records and ended up including 36 studies. Of those 36, one was clinical and the remaining 35 were preclinical. That proportion tells you more about the current state of knowledge than any individual result does.
How does BPC-157 peptide work?
Explaining how a substance works usually starts with its receptor, the protein it binds to, and traces the chain of events that follows inside the cell. For BPC-157 that first step is missing: more than thirty years of research have not identified such a receptor. In its place the literature describes several signalling routes the peptide appears to affect: vessel formation through VEGFR2, the nitric oxide system, fibroblast migration through the FAK–paxillin pathway, and expression of the growth hormone receptor. Each accounts for part of what has been observed, and none accounts for all of it. That is what reviewers mean when they describe the proposed BPC-157 peptide mechanism of action as pleiotropic: the peptide appears to affect several processes at once rather than through one common pathway.
Angiogenesis and VEGFR2
Nothing rebuilds without a blood supply, so angiogenesis was an early place to look. A group in Taiwan tested this in rats with hind-limb ischaemia: treated animals regained perfusion faster, and the affected muscle showed increased vessel formation.Cell culture suggested what might lie behind it. VEGF itself did not rise. What increased was expression of its receptor, VEGFR2, and how readily the cells pulled that receptor from their surface inside themselves, a process known as internalisation. The VEGFR2–Akt–eNOS pathway switched on at the same time. When that uptake was blocked with dynasore, a compound that stops cells taking receptors in, both the signalling and the cells’ ability to line up into the tube-like structures that precede vessels disappeared. That points to a role for receptor internalisation, without ruling other routes out.An earlier result from Zagreb went the other way: no direct angiogenic effect in their own cell experiments, although healing tissue in live animals did show changes in angiogenesis. The discrepancy probably says more about the setting than about the peptide, since a real injury presents many signals at once and an isolated culture almost none.
Nitric oxide signalling
Nitric oxide is the second theme that keeps returning. In experiments on isolated rat aorta, BPC-157 relaxed the vessel, more strongly at higher concentrations. Control manipulations showed that the effect disappears without the endothelial lining and without nitric oxide, which places it squarely in that signalling pathway.Work in endothelial cells pointed to a possible mechanism. The enzyme eNOS, which produces nitric oxide, is normally held inactive by a protein called caveolin-1. Exposure to the peptide loosened that interaction and increased phosphorylation of Src, caveolin-1 and eNOS. The result is a second route to eNOS activation, possibly independent of VEGF. Which of the two matters more, and under what conditions, has not been established.
Fibroblast migration and the FAK–paxillin pathway
Tendons heal slowly for a fairly practical reason. The repair is done by fibroblasts, the cells that make collagen and build new tissue from it, and they first have to reach the tear. A tendon’s blood supply is poor, so the journey is a long one.In 2011 researchers at Chang Gung University in Taiwan asked which part of that process BPC-157 might act on: how fast fibroblasts divide, or how fast they move. Rat tendon cells were cultured, some were exposed to the peptide, and the two groups were compared.Movement won. The treated cells did not grow more numerous, but they travelled more readily, spread better across a surface, coped better with stress and migrated out of tissue fragments faster. Inside them, FAK and paxillin were more active, two proteins that handle how a cell grips its surroundings and pulls itself forward.So BPC-157 appears to help repair cells reach an injury rather than multiply faster. Whether that adds up to better healing in a living body, where far more is in play, is another question.
Growth hormone receptor expression
Three years later the same Taiwanese group scanned gene activity in treated tendon cells, a method that checks thousands of genes at once, and found a connection it had not been looking for. Among the genes running more actively than usual was the one for the growth hormone receptor, with the effect increasing both with exposure and over time.So the researchers added growth hormone to see whether those changes mattered. Cells previously exposed to BPC-157 showed greater proliferation in its presence and increased activation of JAK2, a kinase involved in signalling downstream of the receptor.The implication is subtler than it first appears. The peptide may alter how tendon cells respond to growth hormone already present in their environment, which is a different claim from saying it stimulates growth hormone production or produces systemic hormonal effects.Two further research directions, involving inflammatory cytokines and ERK1/2 signalling, also appear in reviews. Their contribution to the overall biological response is less clearly characterised than the pathways above.
What have BPC-157 animal studies revealed?
Knowing which pathways become active in a dish is one thing. Whether an injured animal actually recovers better is another question, and it is answered through experiments in live animals, mostly rat injury models, supported by cell and explant culture.
Tendon injuries
Most of the work on BPC-157 has used a model of a severed Achilles tendon in rats. The injury reproduces reliably, and recovery can be judged several independent ways, from how the animal moves to how much load the healing tissue takes.In studies from the Zagreb group, treated animals recovered better than controls on all of those measures. The researchers then took on a harder problem: healing at the junction between tendon and bone, which does not happen on its own. Improvement was reported there too, including in animals given corticosteroids, which normally impair repair.For the study of tendon regeneration these are substantial findings. They come from experimentally induced injuries in rats, which do not reproduce every condition involved in human tendon damage.
Ligament injuries
Ligaments pose the same problem in a different place. In experiments from the same group on a damaged collateral ligament of the knee, animals given BPC-157 recovered better than controls, and the result held across different routes of administration.That last point is the interesting one. An effect that survives a change of route is worth investigating further, though it says nothing about absorption, bioavailability or what happens in people.
Muscle, bone and tissue junctions
Muscle and bone continue the same line. A 2025 orthopaedic systematic review pulled together studies in which animals given BPC-157 recovered better than controls after injuries to muscle, tendon, ligament and bone, measured functionally, structurally and biomechanically.A smaller set of experiments looked at the junctions: where muscle becomes tendon, and where tendon attaches to bone. Both heal poorly, because the tissues on either side differ in mechanical properties and in blood supply. Reports of improvement there suggest that whatever the peptide does, it is not confined to one tissue type. Reproduction by independent laboratories remains the decisive test.
Gastrointestinal tract and wounds
None of this began with tendons and ligaments. The peptide came out of gastrointestinal research, and the early experimental literature is concentrated there. That work is also in animals: alcohol- and NSAID-induced damage to the gastric lining in rats, models of inflammatory bowel disease, fistula healing. Treated animals healed better than controls.The results were substantial enough to carry the compound into early clinical development for inflammatory bowel disease under the code PL 14736, which involved people rather than animals and is covered further below. A 2021 review from the Zagreb group described comparable findings in animal models of skin wounds, including burns and incisional wounds.
What do scientific studies show about BPC-157?
The findings are easiest to read by level of evidence, from isolated cells up to controlled trials.Cell experiments and work on isolated tissue answer a narrow question: what happens at the level of the cell itself. That is how the signalling routes and changes in cell behaviour described above were found. Studies on endothelial cells, tendon fibroblasts, tissue fragments and isolated vessels showed which molecules respond to the peptide. Every such system carries the same limitation: cells in a dish do not behave as they do inside a body, where many signals arrive at once.Animal experiments lift part of that limitation. Here you can see how the healing ended: whether the tissue rebuilt its proper structure, how much load it takes, and whether the animal regained normal movement. Across numerous preclinical studies, mostly in rodents, those measures were better in treated animals than in controls. For laboratories conducting similar investigations, Purita Peptides offers peptide BPC-157 for sale for research use only.Then comes the drop. Human evidence consists of small uncontrolled studies offering preliminary observations about symptoms and short-term tolerability, which is a long way from establishing clinical efficacy. Randomised, placebo-controlled trials exist precisely to close that distance, since comparing groups reduces the influence of expectation and of factors nobody thought to measure.Two things are worth keeping in mind when reading the literature as a whole. One is provenance: a substantial share of the animal research comes from a single group in Zagreb, so independent replication carries particular weight, and mechanistic studies from other laboratories broaden the base. The other is the species gap. Differences in metabolism, tissue biology and exposure mean that findings in rats cannot be assumed to hold in people, and no quantity of animal data closes that gap by itself.
BPC-157 studies in humans
Set against decades of animal work, the published human evidence comes to three small pilot studies, none with a control group, alongside two registered clinical trials.All three studies come from a single clinical group in Florida, share the same lead author, the physician Edwin Lee, and were published in the same journal, Alternative Therapies in Health and Medicine.The earliest, from 2021, was a retrospective review of the case notes of 16 patients with chronic knee pain. Most reported less pain afterwards. There was no control group and the data were gathered after the fact, so the study cannot tie that improvement to BPC-157.The second, from 2024, was a prospective pilot in 12 women with interstitial cystitis. Symptoms eased in some of them, though the small sample and the absence of a control group again limit what can be concluded.The third, from 2025, looked at short-term safety and involved just two healthy adults. No adverse effects and no biomarker changes were recorded during the observation period. That is preliminary tolerability information and nothing more.Several human clinical trials involving BPC-157 have been registered, and the contrast between two of them is instructive. PCO-02, registered as NCT02637284 in 2015, was designed as a Phase 1 study of safety and pharmacokinetics in 42 healthy volunteers. No results have been publicly posted, and its registry status remains unknown. BPC-HAMSTR, registered as NCT07437547, is a Phase 2 randomised, blinded, placebo-controlled study in adults with acute hamstring strain, with 120 participants planned. The registry listed it as recruiting in February 2026, with no published results at that time.Earlier investigations of inflammatory bowel disease under the development code PL 14736 were reported mainly through conference abstracts rather than full clinical papers.The hamstring study matters more than its size suggests. Its controlled design should allow a more reliable comparison of outcomes than any of the small observational reports available so far, and its findings will need evaluating once they are published.
BPC-157 safety and research considerations
Is BPC-157 safe? It is a reasonable question, but the available human evidence is still too limited to give a definitive answer.Most of the available tolerability information comes from animal experiments. A preclinical safety evaluation involving mice, rats, rabbits and dogs reported no serious toxic effects under the conditions tested, and pharmacokinetic research reported no visible signs of toxicity in its repeated-exposure experiments. Those findings contribute to the experimental safety literature without establishing safety in people.The one human safety-focused pilot involved two participants and a short observation period. It reported no adverse effects or biomarker changes, but a sample that size cannot detect uncommon reactions or say anything about long-term consequences. An absence of reported problems is not demonstrated safety, and long-term exposure has not been adequately studied in humans.
BPC-157 as a research-use-only peptide
Research use only means what it says: the material is meant for laboratory investigation, not for established clinical use. BPC-157 carries that designation because its effects and safety in people have not been adequately established.A practical consequence follows, and it gets less attention than it deserves. Thirty years of accumulated data are only comparable if a researcher can say what was actually in the vial. For a research peptide, that makes analytical verification and batch documentation count for as much as the experimental protocol. A useful certificate of analysis answers a few specific questions. Understanding peptide COA testing helps researchers interpret the reported results and the limits of each analytical method.Is it the right molecule? Mass spectrometry helps verify molecular identity by comparing measured mass-related characteristics with those expected for the sequence, roughly 1,419 Da. Methods such as lc-ms peptide testing can provide additional analytical information about the sample.How pure is the batch? High-performance liquid chromatography separates the contents and shows what else is in there. A purity percentage obtained through HPLC purity analysis is worth having, though on its own it confirms neither the identity of the molecule nor how much peptide the vial holds.How much peptide is actually present? That is a measurement of its own, and it rarely matches the total mass of the sample, because water and counterions take up part of it. The documented form matters here as well, since a free peptide and an acetate salt differ in weight per milligram.Then there is the question of who ran the tests. A laboratory with no commercial stake in the outcome provides a check that no supplier can provide for itself. Purita Peptides offers peptide BPC-157 for sale with analytical documentation from an independent laboratory for research use only. Worth remembering, though, that a certificate confirms only the parameters it reports, and only for the batch it names, so the methods, the results and the batch number need to be read together.Storage is the other half of keeping research material consistent, and our separate guide to peptide storage covers what matters for lyophilised peptides.
Conclusion
BPC-157 has been examined across a wide range of experimental models, from severed tendons and ligaments to gastrointestinal and vascular injury. Work on VEGFR2, nitric oxide signalling, the FAK–paxillin pathway and the growth hormone receptor has added detail to the proposed mechanisms, including from laboratories outside the original Zagreb group.Three questions now matter more than the rest: whether the reported animal findings can be reproduced independently, which molecular interactions account for the observed effects, and what properly controlled human trials will show.The first of those is where research material stops being a technicality. Replication means one laboratory obtaining the result another laboratory reported, and that comparison only holds if both worked with the same molecule at comparable purity and content. A difference in outcome tells you something when the material is documented, and nothing at all when it is not. For anyone adding to this literature rather than reading it, that is the practical link between thirty years of published work and the product that reaches the bench.Scientific referencesStaresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. doi:10.1016/S0736-0266(03)00110-4Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155–1161. doi:10.1002/jor.21107Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. doi:10.1152/japplphysiol.00945.2010Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. doi:10.3390/molecules191119066Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323–333. doi:10.1007/s00109-016-1488-yHsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. doi:10.1038/s41598-020-74022-ySeiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol. 2021;12:627533. doi:10.3389/fphar.2021.627533Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide – literature and patent review. Pharmaceuticals. 2025;18(2):185. doi:10.3390/ph18020185Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. doi:10.1177/15563316251355551Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13. PMID: 34324435Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12–17. PMID: 39325560Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20–24. PMID: 40131143Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). doi:10.52628/92.3.15837ClinicalTrials.gov. PCO-02 – Safety and Pharmacokinetics Trial (NCT02637284)ClinicalTrials.gov. BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547)